Road Toward a New Model of Care for Idiopathic Pulmonary Fibrosis in the Lazio Region.

A timely, confirmed diagnosis of Idiopathic Pulmonary Fibrosis (IPF) has a significant impact on the evolution of the disease. The current model of care in the Lazio region (in Italy) was assessed on the basis of real-world data provided by the four reference centers responsible for diagnosing and treating IPF. The 5-year, population-based, retrospective longitudinal study provided the data that is at the basis of the current proposal for a new clinical and therapeutic pathway (DTCP) and has been shared with regional decision makers. A DTCP must be defined and based on four pillars: GPs, pulmonologists, IPF centers, and telemedicine. Each must play a role within a sort of hub-and-spoke model. IPF centers remain the hubs, while spokes are identified in trained GPs and pulmonologists.

Informations de copyright

Copyright © 2022 Di Bidino, Rogliani, Sebastiani, Ricci, Varone, Sgalla, Iovene, Bruni, Flore, D'Ascanio, Cavalli, Savi, Di Michele, Cicchetti and Richeldi.

Déclaration de conflit d'intérêts

All authors has received a research grants from ALTEMS to participate to the study. For other studies, LR has received consulting fees from Boehringer Ingelheim, Roche, FibroGen, Celgene, RespiVant, Nitto, Bristol Myers Squibb, Pliant Therapeutics, Veracyte, CSL Behring, Novartis, and speaker honorarium from Boehringer Ingelheim, Roche, Zambon, CSL Behring and participated in Data Safety Monitoring Board or Advisory Boards for Boehringer Ingelheim, Roche, FibroGen, Veracyte. Departement of Experimental Medicine - Respiratory Medicine (Università di Roma “Tor Vergata”) was funded by Almirall, Boehringer Ingelheim, Chiesi Farmaceutici, Novartis, and Zambon. PR participated as a lecturer in scientific meetings and courses under the sponsorship of Almirall, AstraZeneca, Biofutura, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Menarini Group, Mundipharma, and Novartis and as an advisor in scientific meetings and courses under the sponsorship of Almirall, AstraZeneca, Biofutura, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Menarini Group, Mundipharma, and Novartis. AS has received consulting fee from Boehringer Ingelheim, Roche and participated in Data Safety Monitoring Board or Advisory Boards for Roche. Then received support for attending meetings and/or travel from Roche. FV has received a speaker honorarium from from Boehringer Ingelheim, Roche. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.